Cargando…

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation and signaling. A combination of HER2 targetin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalil, Hilal S., Langdon, Simon P., Goltsov, Alexey, Soininen, Tero, Harrison, David J., Bown, James, Deeni, Yusuf Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342785/ https://www.ncbi.nlm.nih.gov/pubmed/27713148 http://dx.doi.org/10.18632/oncotarget.12425

Ejemplares similares

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies
por: Khalil, Hilal S., et al.
Publicado: (2016)

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy
por: Goltsov, Alexey, et al.
Publicado: (2014)

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib
por: Kankia, Ibrahim H., et al.
Publicado: (2017)

Customizing the Therapeutic Response of Signaling Networks to Promote Antitumor Responses by Drug Combinations
por: Goltsov, Alexey, et al.
Publicado: (2014)

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
por: Kankia, Ibrahim H., et al.
Publicado: (2021)

Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies
por: Paramasivan, Poornima, et al.
Publicado: (2019)

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
por: Lebedeva, Galina, et al.
Publicado: (2012)

A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
por: Bown, James L., et al.
Publicado: (2016)

In Silico Screening of Nonsteroidal Anti-Inflammatory Drugs and Their Combined Action on Prostaglandin H Synthase-1
por: Goltsov, Alexey, et al.
Publicado: (2010)

Diagnostics of Ovarian Tumors in Postmenopausal Patients
por: Mustafin, Chingis, et al.
Publicado: (2022)

Role of NRF2 in Ovarian Cancer
por: Tossetta, Giovanni, et al.
Publicado: (2022)

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk
por: Katz, E, et al.
Publicado: (2010)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
por: Yang, Yun, et al.
Publicado: (2020)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023)

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2012)

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
por: Sun, Jiangang, et al.
Publicado: (2022)

Is there a role for immunotherapy in HER2-positive breast cancer?
por: Holgado, Esther, et al.
Publicado: (2018)

Clinical development of immunotherapies for HER2(+) breast cancer: a review of HER2-directed monoclonal antibodies and beyond
por: Costa, Ricardo L. B., et al.
Publicado: (2020)

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
por: Tian, Ziyin, et al.
Publicado: (2022)

Bioactivity of recombinant humanized monoclonal antibody against HER2 in-vivo and in-vitro and its mechanism of action in ovarian cancer
por: Zeng, Jinfeng, et al.
Publicado: (2023)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

The Antioxidative Action of ZTP by Increasing Nrf2/ARE Signal Pathway
por: Yang, Liang, et al.
Publicado: (2019)

Three Grand Challenges in High Throughput Omics Technologies
por: Suravajhala, Prashanth, et al.
Publicado: (2022)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
por: Huang, Rui, et al.
Publicado: (2015)

Alkaloids as Natural NRF2 Inhibitors: Chemoprevention and Cytotoxic Action in Cancer
por: Gjorgieva Ackova, Darinka, et al.
Publicado: (2023)

Targeting Nrf2 may reverse the drug resistance in ovarian cancer
por: Li, Danjie, et al.
Publicado: (2021)

HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction
por: Kang, Hyo Jin, et al.
Publicado: (2014)

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
por: Arab, Atefeh, et al.
Publicado: (2020)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
por: Agostinetto, Elisa, et al.
Publicado: (2022)

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
por: Pous, Anna, et al.
Publicado: (2023)

Immunotherapy with MVA-BN(®)-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells
por: Mandl, Stefanie J., et al.
Publicado: (2011)

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
por: Chang, Kuang-Leei, et al.
Publicado: (2016)

The application of HER2 and CD47 CAR-macrophage in ovarian cancer
por: Chen, Yizhao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_seiiec3qealo6qkf0kd4980152